** Shares in Eurofins Scientific EUFI.PA slip around 3%
after the Luxembourg-based company reported lower than expected
FY revenue and organic growth short of its own guidance
** FY revenue came in at 6.95 billion euros ($7.24 billion)
vs IBES estimate of 6.97 billion
** Midcap Partners notes the organic growth of 4.7% was
"significantly" below the company's own forecast of 6.5% growth
announced in the 2027 plan
** Broker says the group's performance is "still off the
mark", adding it struggles with continued weak level of organic
growth, issues with governance and "unconvincing" operational
leverage
** "Eurofins still seems uninvestable to us," says Midcap
** The stock is among top losers on French blue chip index
CAC40 .FCHI
($1 = 0.9598 euros)
(Reporting by Mateusz Rabiega)
((Mateusz.rabiega@thomsonreuters.com))